摘要
近年来,经导管瓣膜病的介入治疗得到了快速发展,新的治疗器械不断涌现,成为与外科手术并驾齐驱的一线治疗手段。虽然中国的经导管瓣膜病介入治疗起步相对比较晚,但是发展的速度比较快,已取得不少令人瞩目的成绩。该文将介绍中国经导管介入治疗在瓣膜病中的应用现状,包括了主动脉瓣疾病、二尖瓣疾病、肺动脉瓣疾病及三尖瓣疾病。
In recent years,the transcatheter interventional therapy of valvular disease has been developed rapidly,and new therapeutic devices are emerging,which has become the first-line treatment in parallel with surgery.Although the interventional therapy of valve disease in China started relatively late,the development speed is relatively fast,and many remarkable achievements has been accomplished.This article will introduce the application of transcatheter intervention in valvular diseases in China,including aortic valve disease,mitral valve disease,pulmonary valve disease and tricuspid valve disease.
作者
韩雅玲
徐凯
HAN Yaling;XU Kai(Department of Cardiology,General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,P.R.China)
出处
《华西医学》
CAS
2020年第9期1035-1038,共4页
West China Medical Journal
基金
辽宁省自然科学基金(2020-MS-040)。
关键词
经导管
瓣膜病
介入治疗
Transcatheter
Valve disease
Interventional therapy